GSK plc (NYSE: GSK), a leading global pharmaceutical company, continues to bolster its pipeline through strategic external partnerships. The US major has recently signed an agreement with US biotech Rgenta Therapeutics to discover and develop novel RNA-targeted small molecule splice modulators, adding to its earlier antibody drug conjugate (ADC) option deal with Duality Biologics this week.
Financial Terms and Milestones of the Agreement
Under the terms of the agreement with Rgenta, the biotech will receive up to USD 46 million in cash upfront and pre-option milestone payments. Rgenta is also eligible to receive nearly USD 500 million per target in option exercise, research, development, regulatory, and commercial milestone payments, plus tiered royalties and a future equity investment. This significant investment underscores GSK’s commitment to advancing innovative therapies.
Expanding the Alliance and Development Responsibilities
GSK has the option to expand the alliance to include additional targets, broadening the scope of the partnership. Rgenta will utilize its proprietary discovery platform to develop novel oral RNA-targeting small molecule splice modulators against multiple targets nominated by GSK. Following GSK’s exercise of its options, GSK will take on the responsibility for further development and commercialization of any drug candidates that emerge from the alliance.-Fineline Info & Tech
